SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
AMENDMENT NO. 2
Under the Securities Exchange Act of 1934
CORTECH, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.002 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
22051J 10 0
-----------------
(CUSIP Number)
Rebecca R. Tilden,Esq.
Vice President and Secretary, Hoechst Marion Roussel, Inc.
Vice President and Assistant Secretary, HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
(816) 966-4000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 8, 1997
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box. [ ]
Page 1 of 5
There is no Exhibit Index
<PAGE> 2
CUSIP No. 22051J 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 0
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 0
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 0
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 0
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 3
CUSIP No. 22051J 10 0
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 0
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 0
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 0
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 0
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 4
This Amendment (the "Amendment") to the Statement on Schedule 13D (the
"Schedule 13D") with respect to the Common Stock of Cortech, Inc. (the
"Issuer"), is filed jointly by Hoechst Marion Roussel, Inc., a Delaware
corporation ("HMRI"), and HMR Pharma, Inc., a Delaware corporation
("Pharma"), and is filed solely to report the termination of the Schedule
13D filing obligation of HMRI and Pharma with respect to beneficial
ownership of securities of the Issuer. The filing of this Amendment on
behalf of Pharma shall not be construed as an admission that Pharma is or
was, for the purposes of Section 13(d) of the Securities Exchange Act of
1934, the beneficial owner of any securities covered by this the Schedule
13D.
Item 5 of the Schedule 13D is hereby amended to read in its entirety
as follows.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
- ------- ------------------------------------
In a sale concluded on October 8, 1997, HMRI sold in a private
transaction (i) all 1,556,757 shares of Common Stock of the Issuer owned by
it at a price of $0.65 per share and (ii) all warrants to purchase an
additional 562,576 shares of Common Stock of the Issuer owned by it at a
price of $0.02 per underlying share. HMRI and Pharma ceased to be the
actual or deemed beneficial owners of more than five percent of the
Issuer's Common Stock on October 8, 1997.
<PAGE> 5
SIGNATURES
----------
After reasonable inquiry and to the best of their knowledge and
belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
HOECHST MARION ROUSSEL, INC.
Date: October 8, 1997 By: /s/ Pierre Legault
Vice President and
Chief Financial Officer
HMR PHARMA, INC.
Date: October 8, 1997 By: /s/ Kevin M. Hartley
Vice President and
Treasurer
